gefitinib has been researched along with Endometrial Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baron, AT; Darcy, KM; Fischer, E; Godwin, AK; Hanjani, P; Leslie, KK; Maihle, NJ; Mannel, RS; Schilder, RJ; Sill, MW; Singh, M; Tewari, KS; Wilken, JA | 1 |
| Brown, J; Gaikwad, A; Ramondetta, LM; Smith, JA; Wolf, JK | 1 |
| Ai, Z; Teng, Y; Tong, J; Wang, J; Xu, Y | 1 |
| Albitar, L; Brachova, P; Dai, D; Ianzini, F; Kosmacek, EA; Laidler, LL; Leslie, KK; Liu, D; Mackey, MA; Meng, X; Wang, X; Xiong, Z; Yang, S; Zhang, Y; Zhu, D | 1 |
| Abdallah, R; Albitar, L; Laidler, LL; Leslie, KK | 1 |
| Albitar, L; Carter, MB; Davies, S; Leslie, KK | 1 |
1 trial(s) available for gefitinib and Endometrial Neoplasms
| Article | Year |
|---|---|
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Endometrial Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Survival Rate | 2013 |
5 other study(ies) available for gefitinib and Endometrial Neoplasms
| Article | Year |
|---|---|
In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; Endometrial Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endometrial Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Phosphorylation; Quinazolines; Receptors, Progesterone; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Endometrial Neoplasms; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Mitosis; Paclitaxel; Pteridines; Quinazolines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Endometrial Neoplasms; Epidermal Growth Factor; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Phosphoproteins; Quinazolines; Signal Transduction | 2005 |
Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.
Topics: Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gefitinib; Genes, Tumor Suppressor; Humans; PTEN Phosphohydrolase; Quinazolines; Retinoblastoma Protein; Transfection; Tumor Suppressor Protein p53 | 2007 |